Literature DB >> 25600437

Fine-tuning Tumor Immunity with Integrin Trans-regulation.

Joseph M Cantor1, David M Rose2, Marina Slepak2, Mark H Ginsberg1.   

Abstract

Inefficient T-cell homing to tissues limits adoptive T-cell immunotherapy of solid tumors. αLβ2 and α4β1 integrins mediate trafficking of T cells into tissues via engagement of ICAM-1 and VCAM-1, respectively. Inhibiting protein kinase A (PKA)-mediated phosphorylation of α4 integrin in cells results in an increase in αLβ2-mediated migration on mixed ICAM-1-VCAM-1 substrates in vitro, a phenomenon termed "integrin trans-regulation." Here, we created an α4(S988A)-bearing mouse, which precludes PKA-mediated α4 phosphorylation, to examine the effect of integrin trans-regulation in vivo. The α4(S988A) mouse exhibited a dramatic and selective increase in migration of lymphocytes, but not myeloid cells, to sites of inflammation. Importantly, we found that the α4(S988A) mice exhibited a marked increase in T-cell entry into and reduced growth of B16 melanomas, consistent with antitumor roles of infiltrating T cells and progrowth functions of tumor-associated macrophages. Thus, increased α4 trans-regulation of αLβ2 integrin function biases leukocyte emigration toward lymphocytes relative to myeloid cells and enhances tumor immunity. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25600437      PMCID: PMC5955000          DOI: 10.1158/2326-6066.CIR-13-0226

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  35 in total

1.  Localized alpha4 integrin phosphorylation directs shear stress-induced endothelial cell alignment.

Authors:  Lawrence E Goldfinger; Eleni Tzima; Rebecca Stockton; William B Kiosses; Kayoko Kinbara; Eugene Tkachenko; Edgar Gutierrez; Alex Groisman; Phu Nguyen; Shu Chien; Mark H Ginsberg
Journal:  Circ Res       Date:  2008-06-26       Impact factor: 17.367

Review 2.  Ex vivo gene transfer for improved adoptive immunotherapy of cancer.

Authors:  Minhtran C Ngo; Cliona M Rooney; Jeffrey M Howard; Helen E Heslop
Journal:  Hum Mol Genet       Date:  2011-03-17       Impact factor: 6.150

Review 3.  Generation, expansion, migration and activation of mouse B1 cells.

Authors:  S Fagarasan; N Watanabe; T Honjo
Journal:  Immunol Rev       Date:  2000-08       Impact factor: 12.988

4.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Authors:  Renier J Brentjens; Isabelle Rivière; Jae H Park; Marco L Davila; Xiuyan Wang; Jolanta Stefanski; Clare Taylor; Raymond Yeh; Shirley Bartido; Oriana Borquez-Ojeda; Malgorzata Olszewska; Yvette Bernal; Hollie Pegram; Mark Przybylowski; Daniel Hollyman; Yelena Usachenko; Domenick Pirraglia; James Hosey; Elmer Santos; Elizabeth Halton; Peter Maslak; David Scheinberg; Joseph Jurcic; Mark Heaney; Glenn Heller; Mark Frattini; Michel Sadelain
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

Review 5.  Homing of antibody secreting cells.

Authors:  Jason G Cyster
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

6.  A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.

Authors:  Vita M Golubovskaya; Carl Nyberg; Min Zheng; Frederick Kweh; Andrew Magis; David Ostrov; William G Cance
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

7.  Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.

Authors:  Elizabeth A Beierle; Xiaojie Ma; Jerry Stewart; Carl Nyberg; Angelica Trujillo; William G Cance; Vita M Golubovskaya
Journal:  Cell Cycle       Date:  2010-03-14       Impact factor: 4.534

8.  Lymphocyte migration in lymphocyte function-associated antigen (LFA)-1-deficient mice.

Authors:  C Berlin-Rufenach; F Otto; M Mathies; J Westermann; M J Owen; A Hamann; N Hogg
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

9.  Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow.

Authors:  P A Koni; S K Joshi; U A Temann; D Olson; L Burkly; R A Flavell
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

10.  Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice.

Authors:  Ana Caterina Parente-Pereira; Jerome Burnet; David Ellison; Julie Foster; David Marc Davies; Sjoukje van der Stegen; Sophie Burbridge; Laura Chiapero-Stanke; Scott Wilkie; Stephen Mather; John Maher
Journal:  J Clin Immunol       Date:  2011-04-20       Impact factor: 8.317

View more
  8 in total

1.  VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1.

Authors:  Oisun Jung; DeannaLee M Beauvais; Kristin M Adams; Alan C Rapraeger
Journal:  J Cell Sci       Date:  2019-10-28       Impact factor: 5.285

2.  Matrix Metalloproteinase 8: Could it Benefit the CAR-T Cell Therapy of Solid Tumors?- a- Commentary on Therapeutic Potential.

Authors:  Alireza Mardomi; Saeid Abediankenari
Journal:  Cancer Microenviron       Date:  2018-03-27

3.  Lymphocyte integrin expression differences between SIRS and sepsis patients.

Authors:  D S Heffernan; S F Monaghan; Alfred Ayala
Journal:  Ir J Med Sci       Date:  2016-10-31       Impact factor: 1.568

Review 4.  Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment.

Authors:  Heidi Harjunpää; Marc Llort Asens; Carla Guenther; Susanna C Fagerholm
Journal:  Front Immunol       Date:  2019-05-22       Impact factor: 7.561

Review 5.  Teaching an old dog new tricks: next-generation CAR T cells.

Authors:  Nicholas Tokarew; Justyna Ogonek; Stefan Endres; Michael von Bergwelt-Baildon; Sebastian Kobold
Journal:  Br J Cancer       Date:  2018-11-09       Impact factor: 7.640

Review 6.  Syndecans and Their Synstatins: Targeting an Organizer of Receptor Tyrosine Kinase Signaling at the Cell-Matrix Interface.

Authors:  Alan C Rapraeger
Journal:  Front Oncol       Date:  2021-10-27       Impact factor: 6.244

Review 7.  Integrin β1 in Pancreatic Cancer: Expressions, Functions, and Clinical Implications.

Authors:  Jiajia Li; Liyao Peng; Qun Chen; Ziping Ye; Tiantian Zhao; Sicong Hou; Jianguo Gu; Qinglei Hang
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

Review 8.  β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer.

Authors:  Anne-Florence Blandin; Guillaume Renner; Maxime Lehmann; Isabelle Lelong-Rebel; Sophie Martin; Monique Dontenwill
Journal:  Front Pharmacol       Date:  2015-11-24       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.